UroGen Pharma Ltd. URGN
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 100.27% | 52.92% | 21.45% | 8.00% | 10.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.27% | 52.92% | 21.45% | 8.00% | 10.85% |
| Cost of Revenue | 59.92% | 50.33% | 40.15% | 33.73% | 25.48% |
| Gross Profit | 105.50% | 53.22% | 19.41% | 5.23% | 9.21% |
| SG&A Expenses | 25.55% | 34.37% | 29.19% | 34.88% | 35.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.85% | 25.15% | 26.10% | 32.19% | 31.58% |
| Operating Income | 45.57% | -1.27% | -30.50% | -58.01% | -53.68% |
| Income Before Tax | 34.95% | -2.25% | -23.68% | -45.18% | -37.55% |
| Income Tax Expenses | -111.38% | -260.44% | -97.25% | -25.64% | 5.33% |
| Earnings from Continuing Operations | 37.00% | 3.76% | -20.98% | -42.70% | -36.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.00% | 3.76% | -20.98% | -42.70% | -36.43% |
| EBIT | 45.57% | -1.27% | -30.50% | -58.01% | -53.68% |
| EBITDA | 45.70% | -1.24% | -30.63% | -58.50% | -54.42% |
| EPS Basic | 39.40% | 10.08% | -6.68% | -18.50% | -5.87% |
| Normalized Basic EPS | 36.93% | 3.91% | -9.69% | -20.07% | -5.99% |
| EPS Diluted | 39.40% | 10.08% | -6.68% | -18.50% | -5.87% |
| Normalized Diluted EPS | 36.93% | 3.91% | -9.69% | -20.07% | -5.99% |
| Average Basic Shares Outstanding | 4.70% | 7.42% | 12.30% | 18.54% | 29.42% |
| Average Diluted Shares Outstanding | 4.70% | 7.42% | 12.30% | 18.54% | 29.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |